Public Policy Resources

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources


Photo of female cancer patient

Patient Quality of Life

ACS CAN advocates for policies that improve the lives of cancer patients by making treatment of their pain and other symptoms and coordination of their care standard protocol throughout their treatment for cancer, starting at the point of diagnosis.


This table lists key studies and review articles that examine the effect that the addition of palliative care has on overall patient costs. While results vary, the addition of palliative care typically either reduces overall costs or is cost neutral.

Our latest survey finds that female cancer patients are less satisfied with the quality of their cancer care than male cancer patients and are more likely to report that their symptoms were not taken seriously and that they had to prove their symptoms to providers.

ACS CAN submitted comments regarding the Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids. While we support certain changes in the Guideline - including a clearer exemption for cancer patients and patients receiving palliative care - we continue to have concerns about the misapplication of this and the previous Guideline. 

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) Draft Guidance on Decentralized Clinical Trials. 

These consensus recommendations endorsed by 12 organizations identify key steps to improve equitable pharmacogenomic (PGx) discovery and  implementation.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on Pharmacogenomic Data Submissions Draft Guidance for Industry. 

Photo of ACS CAN Volunteers participating in health care reform Lobby Day event

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

ACS CAN strongly advocated for inclusion in the Inflation Reduction Act of both an annual cap on total Part D out-of-pocket costs and a mechanism that would allow an enrollee the option to pay the required cost-sharing in capped monthly installments because we know from research that hig

ACS CAN is making cancer a top priority for public officials and candidates at the federal, state, and local levels.

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

The PSA Screening for HIM Act  (H.R. 1826/S. 2821) would remove out-of-pocket costs for prostate cancer screening for those at highest risk for the disease. 

Critical steps are needed to increase lung cancer screening rates across the country and also increasing to access comprehensive cessation benefits, especially among individuals with limited incomes that are disproportionately burdened by lung cancer.

ACS CAN supports H.R. 4286 to eliminate barriers and increase access to lung cancer screening and expand coverage for tobacco cessation.

Breast cancer is the second most diagnosed cancer among women in the U.S. and the second leading cause of cancer death among women after lung cancer. Ensuring breast cancer screening services ― including diagnostic and follow-up testing ― are covered without no cost-sharing is essential to increasing access and expanding coverage of breast cancer screening.

ACS CAN supports H.R. 3086 to increase access to no cost breast cancer screening, diagnostic and follow-up testing.